BENDAMUSTINE HCL
Manufacturer: Meitheal Pharmaceuticals Inc.
Score: 141.0
Bendamustine hydrochloride is an alkylating agent used for the treatment of patients with chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. The recommended dose is 100 mg/m^2 administered intravenously over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles for CLL, and 120 mg/m^2 administered intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles for NHL. Bendamustine hydrochloride is contraindicated in patients with a known hypersensitivity to bendamustine. The most common adverse reactions are myelosuppression, infections, nausea, vomiting, diarrhea, fatigue, pyrexia, and anemia.
Bendamustine hydrochloride is contraindicated in patients with a known hypersensitivity to bendamustine.
Dose delays, dose modifications, and reinitiation of therapy may be necessary based on hematologic and non-hematologic toxicity.
100 mg/m^2 administered intravenously over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles
120 mg/m^2 administered intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles